Frova Side Effects

Serious Adverse Side Effects

Frova | Frovatriptan Succinate has some very serious adverse side effects associated with it, such as:

Cardiovascular side effects like heart attacks, restriction of blood flow to the heart, and irregular heartbeats

Common Adverse Side Effects

Frova | Frovatriptan Succinate has more common and less severe adverse side effects associated with it, such as:

Neurological side effects like dizziness
Other side effects like fatigue

Warnings & Recalls for Frova

Contraindications

The contraindications associated with Frova | Frovatriptan Succinate are as follows:

Ergot agent or serotonin agonist 5HT1 use within 24 hours
Hemiplegic or basilar migraines
Hypersensitivity to Frova | Frovatriptan Succinate
Ischemic cardiac, cerebrovascular, or peripheral vascular syndromes
Uncontrolled hypertension
Underlying cardiovascular disease

Who Should Not Take This Drug

Frova | Frovatriptan Succinate should never be taken by the following patients with these preexisting conditions:

Patients without a clear diagnosis of migraines
Patients who are elderly
Patients at risk of ischemic disease due to obesity, diabetes, smoking, high cholesterol or family history
Severe hepatic impairment
Signs and symptoms suggestive of angina or decreased blood flow of the arteries

Pregnancy Warning

Frova | Frovatriptan Succinate has a pregnancy category warning of “C” by the FDA, implying that although it doesn’t pose that much of a risk to the fetus, complications cannot be ruled out.

Frova Treatment and Use

Frova | Frovatriptan Succinate is a drug of the triptan classification which had been developed by Vernalis, specifically for the treatment of migraine headaches and the prevention of menstrual migraines. In North America, this drug is licensed to Endo Pharmaceuticals.

On the year 2007, Frova | Frovatriptan Succinate had a revenue of $52 million.

How This Drug Works

Frova | Frovatriptan Succinate is known to be a selective agonist of the 5-hydroxy-tryptamine (5-HT) receptor, which binds highly with 5-HT(1B) and other receptors. The drug doesn’t affect channel activity which is mediated by certain acids and its shown to have an insignificant binding affinity for benzodiazepine sites. Frova | Frovatriptan Succinate prevents the dilation of both intracranial and extracerebral blood vessels in migraines.

Dosage Information

Pediatric dosing for Frova | Frovatriptan Succinate has not been provided due to the fact that the safety and efficacy of this drug on pediatric patients has not been established.

For adult patients, 2.5mg ORALLY (which may be repeated after 2 hours). The maximum daily dosage prescribed is 7.5mg per day.